(Q44574659)

English

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Stroobants S

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Goeminne J

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Seegers M

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dimitrijevic S

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dupont P

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Nuyts J

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Martens M

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

van den Borne B

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Cole P

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sciot R

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dumez H

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Silberman S

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mortelmans L

13

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

van Oosterom A

14

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2012-2020

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The mechanism of accumulation of tumour-localising radiopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical role of positron emission tomography in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Whole-body FDG-PET imaging in the management of patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum likelihood reconstruction for emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900073-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00073-X

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44574659&oldid=1584555165"